Results 151 to 160 of about 232,598 (258)

TWEAK/Fn14 Signaling Drives Oxidative Cardiac Injury in Systemic Lupus Erythematosus: Evidence From Patient Biomarker Studies, Lupus Mouse Models, and Cardiomyocyte Assays

Arthritis &Rheumatology, EarlyView.
Objective Cardiac involvement is a major cause of morbidity in systemic lupus erythematosus (SLE). Tumor necrosis factor–like weak inducer of apoptosis (TWEAK) is elevated in SLE, but its contribution to lupus‐associated cardiac injury is unclear. We investigated the role of TWEAK/fibroblast growth factor–inducible 14 (Fn14) signaling in SLE‐related ...
Yale Liu, Zhu Yan, Xueting Peng, Meixuan Li, Juan Wang, Yan Zhang, Xiaoqian Hu, Mingzhu Zhou, Kaixuan Ren, Dan Zhang, Xingyi Guo, Yumin Xia, Huanhuan Huo   +12 more
wiley   +1 more source

D- and L-lactate dehydrogenase reactions increase pH to lactate production and decrease pH to pyruvate production. [PDF]

Front Mol Biosci
Robergs R, Nalos M, Kelbich P, Jizerová A, Mervartová I, Vostrý M, Štengl M, Babuška V.   +7 more
europepmc   +1 more source

A Rare RIPK3 Variant Enhances Necroptosis and Promotes Inflammation in a Still Disease–Like Autoinflammatory Syndrome

Arthritis &Rheumatology, EarlyView.
Objective Still disease represents a prototypical polygenic systemic autoinflammatory disease, characterized by recurrent systemic inflammation and dysregulation of innate immunity. Despite extensive clinical characterization, familial clustering Still disease remains unreported.
Longfang Chen, Qihua Dai, Yu Xiao, Jialin Dai, Mengyan Wang, Yuning Ma, Yujie Shen, Zhimo Xu, Jianfen Meng, Xia Chen, Da Yi, Yue Sun, Hui Shi, Honglei Liu, Xiaobing Cheng, Yutong Su, Junna Ye, Huihui Chi, Zhuochao Zhou, Tingting Liu, Jialin Teng, Chengde Yang, Jinchao Jia, Qiongyi Hu   +23 more
wiley   +1 more source

Lactate Dehydrogenase as a Potential Mediator Between Immature Granulocytes and Tumor Burden in Breast Cancer. [PDF]

J Inflamm Res
Liang H, Pan K, Liang X, Wang J, Xie X, Wan N, Lin J.   +6 more
europepmc   +1 more source

Interleukin‐2 Deprived State of Regulatory T cells and Their Recovery by Low‐Dose Interleukin‐2 in Patients With Inflammatory Myopathies

Arthritis &Rheumatology, EarlyView.
Objective Regeneration and expansion of Treg by low‐dose interleukin‐2 (IL‐2) therapy is considered a potential treatment strategy for a wide range of autoimmune diseases. To provide a pathophysiologically‐based rationale for low‐dose IL‐2 therapy, we investigated whether reversible defects in the Treg–IL‐2 axis emerge in inflammatory myopathies ...
Justus Ohmes, Luisa R. Monne, Sara Comdühr, Fynn Gerlach, Hanna Grasshoff, Alexander Dübbers, Antje Müller, Alexander Scheffold, Gabriela Riemekasten, Reza Akbarzadeh, Jens Y. Humrich   +10 more
wiley   +1 more source

Inhibition Profiling of <i>Rhodiola crenulata</i> on Lactate Dehydrogenase Isoenzymes. [PDF]

Molecules
Wei YX, Asgari M, Zhao QF, Zhang SS, Alifujiang Z, Zhang F, Chen XP, Feng CG.   +7 more
europepmc   +1 more source

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

British Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort, Marella C. E. van Ruissen, Lisanne C. A. Smidt, Naomi B. Klarenbeek, Philip H. K. Kremer, Manon A. A. Jansen, Jacobus Burggraaf, Joop M. A. van Gerven, Matthijs Moerland   +8 more
wiley   +1 more source

Lactate dehydrogenase-to-albumin ratio as a potential prognostic indicator in glucocorticoid-treated severe pneumonia: a multicenter retrospective study with external validation. [PDF]

Front Immunol
Lin J, Chen J, Liu Z, Wen Q, Zheng Z, Liu X, Zhu Z, Yang D, Zhou Z, Xiao D, Liu C.   +10 more
europepmc   +1 more source

From anthelmintic to neuro‐oncology: A systematic review of mebendazole repurposing for brain tumour therapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mebendazole (MBZ), a benzimidazole anthelmintic with established clinical use, has emerged as a repurposing candidate for primary brain tumours due to its multimodal anticancer actions and central nervous system penetrance. This systematic review synthesizes preclinical and clinical evidence evaluating MBZ's efficacy, mechanisms of action ...
Ciara B. Blum, Milli McMenamin, Tessa Khoo, John M. Edwin, Prathibha Jose, Liam A. O’Callaghan   +5 more
wiley   +1 more source

Lactate dehydrogenase to albumin ratio as a convenient parameter for predicting the severity of Behçet disease: a cross-sectional study. [PDF]

BMC Immunol
Pala E, Bayraktar M.
europepmc   +1 more source